Juan Pedro Martinez-Barbera
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeting cellular senescence against childhood high-grade glioma (TANGENTIAL)
Open Date: 2023-01-01
Close Date:
Grant: Close
Repurposing the alcohol-abuse drug disulfiram to target a key epigenetic hallmark of Diffuse Midline Glioma
Open Date: 2023-01-01
Close Date: 2026-01-01
Grant: Open
EVEREST 2.0; Paediatric research and Innovation centre for low-grade brain tumours
Open Date: 2022-01-01
Close Date: 2027-01-01
Grant: Close
Exploiting therapeutic targets in paediatric high grade gliomas with H3K27M mutations
Open Date: 2020-01-01
Close Date: 2024-01-01
Grant: Close
Characterisation of the pro-tumorigenic activities of cellular senescence in adamantinomatous craniopharyngioma and preclinical validation of novel therapies
Open Date: 2019-01-01
Close Date: 2026-01-01
Articles (7)
Year:
2025
Year:
2025
Year:
2023
Craniopharyngiomas (CPs) are clinically aggressive tumors because of their invasive behavior and recalcitrant tendency to recur after therapy. There are 2 types based on their distinct histology and molecular features: the papillary craniopharyngioma (PCP), which is associated with BRAF-V600E mutations and the adamantinomatous craniopharyngioma (ACP), characterized by mutations in CTNNB1 (encoding β-catenin). Patients with craniopharyngioma show symptoms linked to the location of the tumor close to the optic pathways, hypothalamus, and pituitary gland, such as increased intracranial pressure, endocrine deficiencies, and visual defects. Treatment is not specific and mostly noncurative, and frequently includes surgery, which may achieve gross total or partial resection, followed by radiotherapy. In cystic tumors, frequent drainage is often required and intracystic instillation of drugs has been used to help manage cyst refilling. More recently targeted therapies have been used, particularly in PCP, but also now in ACP and clinical trials are underway or in development. Although patient survival is high, the consequences of the tumor and its treatment can lead to severe comorbidities resulting in poor quality of life, in particular for those patients who bear tumors with hypothalamic involvement. Accordingly, in these patients at risk for the development of a hypothalamic syndrome, hypothalamus-sparing treatment strategies such as limited resection followed by irradiation are recommended. In this review, we provide an update on various aspects of CP, with emphasis on recent advances in the understanding of tumor pathogenesis, clinical consequences, management, and therapies.
Year:
2022
Year:
2022
Year:
2021
Year:
2020
Collaborators (1)
John Apps
University of Birmingham
Make your next move.
Prepare your application
Review drafts before you send them.